

Gilead Sciences appoints new GM for Korea

14 September 2023 | News

| Former MSD Taiwan M | Managing Director Jae | Yeon Choi has strong | g track record of leadershi | p roles |
|---------------------|-----------------------|----------------------|-----------------------------|---------|
|---------------------|-----------------------|----------------------|-----------------------------|---------|

Gilead Sciences has announced the appointment of Jae Yeon Choi as General Manager (GM), Korea, effective 1st October 2023.

Choi will be responsible for managing Gilead's Korea operations and driving business development across HIV, viral hepatitis, COVID-19, anti-fungal, and cancer. In addition, she will support Gilead's commitment to enhancing wider health and community impact projects in Korea.

Choi brings nearly two decades of experience across a variety of leadership roles in the pharmaceutical industry, including commercial, HR, access and policy, spanning diverse geographical regions including US, China, Taiwan, and Korea.

She joins Gilead from MSD, where she served as Managing Director MSD Taiwan, having driven double digit business growth for two consecutive years. Choi joined MSD in 2017 as External Affairs Lead, Korea, and subsequently took on the role of Oncology Business Unit Director in Korea, developing and building a team that achieved exceptional performance in Immuno-oncology. Prior to MSD, Choi spent eleven years at Eli Lilly last serving as Marketing Director for Eli Lilly in Korea.

With this appointment, Choi will become a member of the Asia 5 Leadership Team, reporting to Dustin Haines, Vice President and General Manager Asia, Middle East, and Turkey.